Technologies

Will Putin Prevent Rebrikov from Attempting Heritable Genome Editing?

By Pete Shanks | 10.08.2019
Biopolitical Times
The Russian molecular biologist who wants to edit the genomes of human embryos is getting impatient with authorities who won't yet let him go ahead.
Policies

U.S. Government Plans to Collect DNA from Detained Immigrants

By Caitlin Dickerson, The New York Times | 10.02.2019

Aggregated News

The Department of Homeland Security said it would begin collecting genetic data on hundreds of thousands of immigrants in federal detention facilities.
Genomics

Despite Calls for a Moratorium, More ‘Three-Parent’ Babies Expected Soon

By Emily Mullin, One Zero | 09.16.2019

Aggregated News

At least 10 babies have been born to apparently infertile women as a result of a controversial in vitro fertilization...

Assisted Reproduction
Black and white ultrasound image with a small fetus in the middle

The Ethical Case for Having a Baby With Down Syndrome

By Chris Kaposy, New York Times | 04.16.2018

CGS-authored

Society
5 Individuals are sitting around a white coach work space all engaging in conversation.

Employees Jump at Genetic Testing. Is That a Good Thing?

By Natasha Singer, New York Times | 04.15.2018

Aggregated News

Society
IVF

Vulnerable would-be parents being sold 'false hope' by overseas IVF clinics, regulator warns

By Alex Matthews-King, The Independent | 04.13.2018

Aggregated News

Assisted Reproduction

“Race” and “IQ” Yet Again

By Pete Shanks | 04.13.2018
Biopolitical Times
Eugenics

Is 23andMe in Trouble? Should They Be?

By Pete Shanks | 04.13.2018
Biopolitical Times
Genetic Selection

So, CRISPR Doesn’t Cause All Those Off-target Effects After All?

By Katie Hasson | 04.13.2018
Biopolitical Times
Human Genetic Modification
Chinese newborn baby in hospital

Chinese Baby Born Four Years After Parents were Killed in Car Accident

By Christina Zhao, Newsweek | 04.12.2018

Aggregated News

Policies
A stack of 3 US dollar bills. The top bill is a $1, then $20, and then another $1.

When curing a disease with gene therapy is bad business

By Antonio Regalado, MIT Technology Review | 04.12.2018

Aggregated News

Society